OncoWise Bio

OncoWise Bio is an Australian biotechnology company specializing in precision oncology and personalized cancer diagnostics. The company develops advanced microfluidic platforms and 3D tumor organoid models designed to recapitulate the tumor microenvironment ex vivo. This technology allows for the functional testing of various oncology drugs on a patient's own cells to predict clinical efficacy before treatment begins. By integrating liquid biopsy techniques, such as the isolation of Circulating Tumor Cells (CTCs), with high-throughput drug screening, OncoWise Bio aims to provide oncologists with actionable data to tailor therapies for individual patients. Their approach addresses the high failure rates of standard-of-care treatments by identifying the most effective drug combinations for specific tumor profiles, particularly in breast and lung cancers.